STOCK TITAN

PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

PDS Biotechnology Corporation has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. The meeting date is more than 30 days after the anniversary of the 2025 Annual Meeting, so the company has set a special deadline for stockholder proposals.

Stockholders seeking to include proposals in the proxy materials under SEC Rule 14a-8 must submit them by June 25, 2026. Eligible proposals must comply with SEC rules and should be sent to the Corporate Secretary at the company’s Princeton, New Jersey headquarters.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
2026 annual meeting date August 10, 2026 Scheduled date for 2026 Annual Meeting of Stockholders
Proposal deadline June 25, 2026 Cutoff for Rule 14a-8 stockholder proposals for proxy inclusion
Company address 303A College Road East, Princeton, NJ 08540 Location for submitting stockholder proposals
Company phone (800) 208-3343 Registrant’s telephone number
Annual Meeting of Stockholders financial
"The Board has scheduled the Company’s 2026 Annual Meeting of Stockholders for August 10, 2026."
Definitive Proxy Statement regulatory
"More detailed information will be set forth in the Company’s Definitive Proxy Statement on Schedule 14A."
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Rule 14a-8 regulatory
"Deadline of June 25, 2026 for the submission of stockholder proposals pursuant to Rule 14a-8 of the Exchange Act."
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
proxy materials financial
"Proposals for inclusion in the Company’s proxy materials for the 2026 Annual Meeting."
Proxy materials are the packet of documents sent to shareholders that explain items to be voted on at a company meeting and include the actual ballot or instructions for casting a vote. Think of them as a voting packet that lays out who’s running the company, major proposals (like pay, mergers, or board changes), and arguments for and against each item. Investors care because those votes shape corporate direction, affect risk and future profits, and can influence share value.
Emerging growth company regulatory
"Emerging growth company Yes No"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2026


PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-37568
26-4231384
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
303A College Road East, Princeton, NJ 08540
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code



(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
Registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes No



Item 8.01.
Other Events.

The board of directors (the “Board”) of PDS Biotechnology Corporation (the “Company”) has scheduled the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for August 10, 2026. More detailed information regarding the 2026 Annual Meeting will be set forth in the Company’s Definitive Proxy Statement on Schedule 14A to be filed with the Securities and Exchange Commission (“SEC”).

Because the date of the 2026 Annual Meeting is more than 30 days from the anniversary date of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), the Company has set a deadline of June 25, 2026 for the submission of stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for inclusion in the Company’s proxy materials for the 2026 Annual Meeting. Proposals of stockholders must also comply with SEC rules regarding the inclusion of stockholder proposals in proxy materials and the Company may omit from its proxy materials any proposal that does not comply with the SEC’s rules. Proposals should be sent to PDS Biotechnology Corporation, 303A College Road East, Princeton, New Jersey 08540, Attention: Corporate Secretary.


Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
   
Date: June 15, 2026
By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name: Frank Bedu-Addo, Ph.D.
 
Title: President and Chief Executive Officer



FAQ

When is PDSB's 2026 Annual Meeting of Stockholders scheduled?

PDS Biotechnology’s 2026 Annual Meeting of Stockholders is scheduled for August 10, 2026. This later-than-usual date triggers special timing rules for shareholder proposals under SEC regulations and will be detailed further in the company’s upcoming definitive proxy statement.

What is the deadline for PDSB stockholder proposals for the 2026 Annual Meeting?

The deadline for PDS Biotechnology stockholder proposals under SEC Rule 14a-8 is June 25, 2026. Proposals received by this date may be eligible for inclusion in the company’s 2026 proxy materials if they fully comply with applicable SEC rules and company requirements.

Why did PDSB set a special proposal deadline for the 2026 Annual Meeting?

PDS Biotechnology set a June 25, 2026 proposal deadline because the 2026 Annual Meeting will occur more than 30 days after the anniversary of the 2025 meeting. SEC rules allow companies to adjust Rule 14a-8 deadlines when annual meeting timing shifts significantly year over year.

Where should PDSB stockholders send Rule 14a-8 proposals for 2026?

Stockholder proposals for PDS Biotechnology’s 2026 Annual Meeting should be mailed to PDS Biotechnology Corporation, 303A College Road East, Princeton, New Jersey 08540, Attention: Corporate Secretary. Proposals must arrive by June 25, 2026 and comply with all SEC Rule 14a-8 requirements.

Will PDSB automatically include all timely proposals in its 2026 proxy?

No. PDS Biotechnology may omit proposals that do not comply with SEC Rule 14a-8. Even if submitted by June 25, 2026, proposals must meet all substantive and procedural requirements for inclusion in the company’s definitive proxy statement for the 2026 Annual Meeting.

Filing Exhibits & Attachments

3 documents